Table 7.
SSTR5 Genotype and Overall Survival of Patients with Resectable Pancreatic Cancer
| Genotype | No. of patients | No. of deaths | MST | P (log- rank) | HR (95% CI)a |
|---|---|---|---|---|---|
| P335L | |||||
| TT | 70 | 38 | 28.2 | Ref | 1.0 |
| CT | 123 | 65 | 35.9 | 0.655 | 0.87 (0.57–1.31) |
| CC | 53 | 36 | 26.0 | 0.235 | 1.35 (0.85–2.13) |
| L48M | |||||
| CC | 238 | 134 | 30.7 | Ref | 1.0 |
| CA | 34 | 17 | 40.0 | 0.583 | 1.04 (0.58–1.87) |
| P109S | |||||
| CC | 224 | 132 | 29.2 | Ref | 1.0 |
| CT | 20 | 7 | - | 0.037 | 0.48 (0.22–1.03) |
| P335L-P109S | |||||
| TT/CT-CC | 177 | 97 | 31.3 | Ref | 1.0 |
| CC-CC | 46 | 34 | 20.2 | 0.036 | 1.57 (1.06–2.34) |
| Any-CT | 19 | 6 | - | 0.050 | 0.46 (0.20–1.05) |
HR, hazard ratio; MST, median survival time.
a
Hazard ratio was adjusted for resection status and CA19-9 level.